基于超声评价的桂枝芍药知母汤联合甲氨蝶呤治疗早期类风湿关节炎疗效观察:随机双盲对照临床试验研究方案
本研究为随机双盲平行组安慰剂对照试验,拟纳入152例早期类风湿关节炎成人患者,按1:1分配至桂枝芍药知母汤联合甲氨蝶呤组或安慰剂联合甲氨蝶呤组,治疗3个月,两组均给予叶酸以预防甲氨蝶呤副作用。主要结局包括血沉、C反应蛋白、肝肾功能、视觉模拟量表、28关节疾病活动度评分、中医症状测量量表及7关节超声评分,旨在利用肌骨超声评估桂枝芍药知母汤的疗效与安全性。
要点
- 桂枝芍药知母汤联合甲氨蝶呤对比安慰剂联合甲氨蝶呤治疗早期类风湿关节炎,疗程3个月。
- 主要结局包括血沉、C反应蛋白、肝肾功能、视觉模拟量表、28关节疾病活动度评分、中医症状量表及7关节超声评分。
- 试验为随机双盲平行组安慰剂对照设计,拟纳入152例早期类风湿关节炎成人患者,按1:1分配。
核心结论
- 本试验旨在阐明桂枝芍药知母汤在早期类风湿关节炎患者中的疗效与安全性。
- 作者希望该试验能为桂枝芍药知母汤治疗类风湿关节炎患者提供初步疗效证据,并有助于研究人员、执业者和患者。
研究设计与样本
- 研究为随机、双盲、平行组、安慰剂对照试验,拟纳入152例早期类风湿关节炎成人患者,按1:1均衡分配。
- 试验组干预为桂枝芍药知母汤联合常规药物甲氨蝶呤,对照组为安慰剂联合常规药物甲氨蝶呤,疗程3个月。
- 两组在治疗期间均接受叶酸以预防甲氨蝶呤的副作用。
- 试验于2020年8月21日在中国临床试验注册中心注册(ChiCTR2000036141),为追溯注册。
关键数值与推荐
- 主要结局包括血沉、C反应蛋白、肝肾功能、视觉模拟量表、28关节疾病活动度评分、中医症状测量量表及7关节超声评分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with the primary clinical symptoms of joint swelling and pain. Early detection of erosion and synovial inflammation at an active stage resulting from RA can prevent damage to the joints and activity restriction. However, there are still many patients who do not respond to these treatments; the development of newer, safer drugs is urgently needed. Compared to Western medicine, Guizhi-Shaoyao-Zhimu decoction has equal or higher efficacy and safety for RA patients. With the widespread use of musculoskeletal ultrasound (MSUS), this technology holds great value for the degree of joint damage in RA patients, guiding the clinical selection of treatments, and assessing of prognosis. Therefore, we designed a double-blinded randomized controlled clinical trial to measure the safety and efficacy of Guizhi-Shaoyao-Zhimu decoction in treating early-stage RA using MSUS. METHODS: This study is a randomized, double-blinded, parallel group, placebo-controlled trial. A total of 152 adult participants with early RA will be enrolled, with balanced treatment allocation (1:1). The experimental intervention will be Guizhi-Shaoyao-Zhimu decoction plus the conventional medicine methotrexate and the control intervention will be placebo plus the conventional drug methotrexate for 3 months. In addition, both groups will receive folic acid during treatment to prevent side effects from methotrexate. The primary outcomes are the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hepatic and renal function, visual analog scale, disease activity score in 28 joints, measurement scale for TCM symptoms, and 7-joint ultrasound score. DISCUSSION: We designed this double-blinded randomized controlled clinical trial to evaluate the efficacy and safety of Guizhi-Shaoyao-Zhimu decoction in RA patients using MSUS. The results of this trial may provide insights into how to improve the clinical symptoms of RA patients and delay further joint destruction. We hope that this trial may provide preliminary evidence of the efficacy of Guizhi-Shaoyao-Zhimu decoction in treating RA patients and that these results aid researchers, practitioners, and patients alike. AIM: The main aim of the study is to clarify the efficacy and safety of Guizhi-Shaoyao-Zhimu decoction in patients with early RA. TRIAL REGISTRATION: Chinese Clinical Trials Register ChiCTR2000036141 . Registered on 21 August 2020 (retroactively registered).
引用
- Shen J, Chen Q, Yang G, et al. Observation of the curative effect of Guizhi-Shaoyao-Zhimu decoction combined with methotrexate in the treatment of early rheumatoid arthritis based on ultrasonic evaluation: study protocol of a randomized, double-blind, controlled clinical trial. Trials. 2021. PMID: 34732237. doi:10.1186/s13063-021-05579-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。